Immuneering Corp (IMRX)
1.56
+0.03
(+1.96%)
USD |
NASDAQ |
May 02, 16:00
1.53
-0.03
(-1.92%)
After-Hours: 20:00
Immuneering Enterprise Value: -40.30M for May 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 01, 2024 | -40.30M |
April 30, 2024 | -43.56M |
April 29, 2024 | -41.78M |
April 26, 2024 | -42.08M |
April 25, 2024 | -43.26M |
April 24, 2024 | -41.19M |
April 23, 2024 | -37.33M |
April 22, 2024 | -34.66M |
April 19, 2024 | -32.29M |
April 18, 2024 | -33.18M |
April 17, 2024 | -31.20M |
April 16, 2024 | -31.78M |
April 15, 2024 | -29.59M |
April 12, 2024 | -24.17M |
April 11, 2024 | -24.76M |
April 10, 2024 | -26.81M |
April 09, 2024 | -21.54M |
April 08, 2024 | -23.59M |
April 05, 2024 | -21.54M |
April 04, 2024 | -16.85M |
April 03, 2024 | -15.39M |
April 02, 2024 | -12.46M |
April 01, 2024 | -5.137M |
March 28, 2024 | -1.037M |
March 27, 2024 | -14.51M |
Date | Value |
---|---|
March 26, 2024 | -15.68M |
March 25, 2024 | -11.58M |
March 22, 2024 | -10.99M |
March 21, 2024 | -5.722M |
March 20, 2024 | -4.258M |
March 19, 2024 | -10.41M |
March 18, 2024 | -10.70M |
March 15, 2024 | -29.73M |
March 14, 2024 | -0.7441M |
March 13, 2024 | 86.52M |
March 12, 2024 | 85.79M |
March 11, 2024 | 88.13M |
March 08, 2024 | 106.43M |
March 07, 2024 | 109.95M |
March 06, 2024 | 101.75M |
March 05, 2024 | 95.89M |
March 04, 2024 | 94.43M |
March 01, 2024 | 94.43M |
February 29, 2024 | 95.89M |
February 28, 2024 | 100.28M |
February 27, 2024 | 102.63M |
February 26, 2024 | 101.45M |
February 23, 2024 | 103.50M |
February 22, 2024 | 102.26M |
February 21, 2024 | 106.94M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-43.56M
Minimum
Apr 30 2024
801.56M
Maximum
Sep 27 2021
162.31M
Average
107.64M
Median
Nov 21 2023
Enterprise Value Benchmarks
Geron Corp | 1.973B |
SELLAS Life Sciences Group Inc | 68.93M |
Elicio Therapeutics Inc | 77.56M |
Vistagen Therapeutics Inc | 0.9997M |
ADMA Biologics Inc | 1.601B |
Enterprise Value Related Metrics
Net Income (Quarterly) | -15.08M |
Total Expenses (Quarterly) | 16.30M |
EPS Diluted (Quarterly) | -0.52 |
Earnings Yield | -121.2% |
Normalized Earnings Yield | -123.08 |